share_log

Morgan Stanley Maintains Underweight on Atea Pharmaceuticals, Lowers Price Target to $4

Morgan Stanley Maintains Underweight on Atea Pharmaceuticals, Lowers Price Target to $4

摩根士丹利维持对Atea Pharmicals的减持,将目标价下调至4美元
Benzinga Real-time News ·  2023/01/24 08:17

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Underweight and lowers the price target from $7 to $4.

摩根士丹利分析师马修·哈里森维持ATEA制药(纳斯达克:AVIR)的减持,并将目标价从7美元下调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发